How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 456-463

  Kiely, Belinda E ^a   Soon, Yu Yang ^a   Tattersall, Martin H N ^a   Stockler, Martin R ^a  

^a SYDNEY CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GEMCITABINE; LAPATINIB; METHOTREXATE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EID: 79952087724     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.2174     Document Type: Review

References (56)

1. Innes S, Payne S: Advanced cancer patients' prognostic information preferences: A review. Palliat Med 23:29-39, 2009
2. Hagerty RG, Butow PN, Ellis PA, et al: Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721-1730, 2004 (Pubitemid 41079812)
3. Fallowfield LJ, Jenkins VA, Beveridge HA: Truth may hurt but deceit hurts more: Communication in palliative care. Palliat Med 16:297-303, 2002 (Pubitemid 34785126)
4. Hancock K, Clayton JM, Parker SM, et al: Truth-telling in discussing prognosis in advanced life-limiting illnesses: A systematic review. Palliat Med 21:507-517, 2007 (Pubitemid 47616606)
5. Stockler MR, Tattersall MH, Boyer MJ, et al: Disarming the guarded prognosis: Predicting survival in newly referred patients with incurable cancer. Br J Cancer 94:208-212, 2006 (Pubitemid 43151537)
6. The Cochrane Collaboration. http://www.cochrane.org/
7. Wilcken N, Dear R: Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. Eur J Cancer 44:2218-2225, 2008
8. UN-SCAN-IT Graph Digitizing Software (ed 6). Orem, UT, Silk Scientific, 1988-2009
9. Alam M, Blinman P, Stockler M: Useful estimates of survival for patients starting first line chemotherapy for advanced non-small-cell lung cancer based on a systematic review of recent randomised trials. 13th World Conference on Lung Cancer, San Francisco, CA, July 31-August 4, 2009
10. Ackland SP, Anton A, Breitbach GP, et al: Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study. J Clin Oncol 19:943-953, 2001 (Pubitemid 32176268)
11. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26: 3950-3957, 2008
12. Andersson M, Madsen EL, Overgaard M, et al: Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer: A randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group - Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 35:39-46, 1999 (Pubitemid 29079489)
13. Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment. J Clin Oncol 18:3115-3124, 2000
14. Batist G, Ramakrishnan G, Rao CS, et al: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454, 2001 (Pubitemid 32202552)
15. Biganzoli L, Cufer T, Bruning P, et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20:3114-3121, 2002 (Pubitemid 34791101)
16. Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355-2364, 1999 (Pubitemid 29368233)
17. Bontenbal M, Creemers GJ, Braun HJ, et al: Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23:7081-7088, 2005
18. Cassier PA, Chabaud S, Trillet-Lenoir V, et al: A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: Results of the ERASME 3 study. Breast Cancer Res Treat 109:343-350, 2008 (Pubitemid 351658936)
19. Conte PF, Guarneri V, Bruzzi P, et al: Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: Results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101:704-712, 2004 (Pubitemid 39030924)
20. Costanza ME, Weiss RB, Henderson IC, et al: Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: Report of a randomized study - Cancer and Leukemia Group B 8642. J Clin Oncol 17:1397-1406, 1999 (Pubitemid 29220845)
21. Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008
22. Ejlertsen B, Mouridsen HT, Langkjer ST, et al: Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: A Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 22:2313-2320, 2004 (Pubitemid 41115387)
23. Fountzilas G, Dafni U, Dimopoulos MA, et al: A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87-99, 2009
24. Fountzilas G, Kalofonos HP, Dafni U, et al: Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517-1526, 2004 (Pubitemid 39409743)
25. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36, 2002 (Pubitemid 34049039)
26. Heidemann E, Stoeger H, Souchon R, et al: Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 13: 1717-1729, 2002 (Pubitemid 35439451)
27. Jassem J, Pieńkowski T, Płuzańska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707-1715, 2001 (Pubitemid 32230871)
28. Katsumata N, Watanabe T, Minami H, et al: Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol 20:1210-1215, 2009
29. Langley RE, Carmichael J, Jones AL, et al: Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 23:8322-8330, 2005
30. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
31. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975, 2003 (Pubitemid 46594123)
32. Namer M, Soler-Michel P, Turpin F, et al: Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer 37:1132-1140, 2001 (Pubitemid 32520887)
33. O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449, 2004 (Pubitemid 38444547)
34. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line singleagent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724-733, 2000 (Pubitemid 30106602)
35. Parnes HL, Cirrincione C, Aisner J, et al: Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol 21:1819-1824, 2003
36. Reyno L, Seymour L, Tu D, et al: Phase III study of N,N-diethyl-2-[4- (phenylmethyl) phenoxy] ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/ recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol 22:269-276, 2004 (Pubitemid 41095091)
37. Robert N, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792, 2006 (Pubitemid 46630577)
38. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649, 2008
39. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
40. Sledge GW Jr, Hu P, Falkson G, et al: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 18:262-266, 2000 (Pubitemid 30056413)
41. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003 (Pubitemid 46621890)
42. Fountzilas G, Papadimitriou C, Dafni U, et al: Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as firstline chemotherapy, in advanced breast cancer: A randomized study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol 19:2232-2239, 2001 (Pubitemid 32372324)
43. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005 (Pubitemid 46207001)
44. Lueck H, Minckwitz GV, Du Bois A, et al: Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 24:18s, 2006 (suppl; abstr 517)
45. Forbes JF, Kennedy J, Pienkowski T, et al: BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J Clin Oncol 24:18s, 2006 (suppl; abstr LBA516)
46. Barnett MM: Does it hurt to know the worst? Psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psychooncology 15:44-55, 2006
47. Clayton JM, Hancock KM, Butow PN, et al: Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust 186:S77, S79, S83-S108, 2007
48. Hagerty RG, Butow PN, Ellis PM, et al: Communicating with realism and hope: Incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 23:1278-1288, 2005 (Pubitemid 46202286)
49. Helft PR: Necessary collusion: Prognostic communication with advanced cancer patients. J Clin Oncol 23:3146-3150, 2005
50. Lamont EB, Christakis NA: Complexities in prognostication in advanced cancer: "To help them live their lives the way they want to." JAMA 290: 98-104, 2003
51. Kutner JS, Steiner JF, Corbett KK, et al: Information needs in terminal illness. Soc Sci Med 48: 1341-1352, 1999 (Pubitemid 29197336)
52. Davey HM, Butow PN, Armstrong BK: Cancer patients' preferences for written prognostic information provided outside the clinical context. Br J Cancer 89:1450-1456, 2003 (Pubitemid 37386599)
53. Saad ED, Katz A, Buyse M: Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials. J Clin Oncol 28:1958-1962, 2010
54. Ghersi D, Wilcken N, Simes J, et al: Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2:CD003366, 2005
55. Stockler MR, O'Connell R, Nowak AK, et al: Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: A placebo-controlled double-blind randomised trial. Lancet Oncol 8:603-612, 2007 (Pubitemid 46995622)
56. Gennari A, Sormani M, Nanni O, et al: Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review. J Clin Oncol 28:15s, 2010 (suppl; abstr 1023)